Stock data
Bicara Therapeutics Inc. (BCAX)
Bicara Therapeutics Inc. (BCAX) reported net income of -US$137.95M for fiscal 2025. The figures below come from the company's SEC filings.
Annual results
Data as of 2025-12-31
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | — | — | -US$155.60M | -US$137.95M | — |
| 2024 | — | — | -US$82.39M | -US$68.00M | — |
| 2023 | — | — | -US$39.89M | -US$51.98M | — |
Quarterly results
Data as of 2026-06-30
| Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| 2026-06-30 | — | -US$55.44M | — |
| 2026-03-31 | — | -US$56.21M | — |
| 2025-12-31 | — | -US$37.39M | — |
| 2025-09-30 | — | -US$36.33M | — |
| 2025-06-30 | — | -US$27.39M | — |
| 2025-03-31 | — | -US$36.85M | — |
| 2024-12-31 | — | -US$20.96M | — |
| 2024-09-30 | — | -US$17.48M | — |
Sources
- Source: SEC EDGAR company facts
Charts, drawing tools, and the P/E calculator are in the app, free to use.